Synthetic organic

lunacalcipol.

InformationLurbinectedin (PM01183) Lurbinectedin (PM01183, PM-1183, LY-01017, Tryptamicidin, Zepsyre, ZEPZELCA), a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell

InformationLurbinectedin (PM01183) Lurbinectedin (PM01183, PM-1183, LY-01017, Tryptamicidin, Zepsyre, ZEPZELCA), a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell

InformationLurbinectedin (PM01183) Lurbinectedin (PM01183, PM-1183, LY-01017, Tryptamicidin, Zepsyre, ZEPZELCA), a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell

InformationLUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.

InformationLUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.

InformationLUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.

luvixasertib.

luvixasertib.

luxeptinib.

luxeptinib.

Competitive melatonin receptor antagonist.